Article, News
Prescient’s (ASX:PTX) PTX-100 demonstrates encouraging clinical activity in T cell lymphomas
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical activity of PTX-100, one of the targeted therapies of Prescient. PTX-100…
Article, News
Prescient Therapeutics PTX-100 continues to exhibit excellent safety profile
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient shows that PTX-100 is safe and effective on difficult to treat T-cell lymphomas
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient Therapeutics’ PTX-100 expansion cohort continues to deliver on safety and clinical movement
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion cohort targeting relapsed and refractory T cell lymphoma (TCL) – and…
Article, News
Prescient Therapeutics reports positive safety data from PTX-100 study on T-cell lymphoma patients
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and refractory T-cell lymphomas (TCL) continues to show encouraging clinical activity…
Article, News
Prescient Therapeutics A$2.5 million top-up placement brings raise total to A$11.3 million
Prescient Therapeutics Ltd (ASX:PTX) has brought in another A$2.5 million in a top-up placement to cater for strong investor demand. Late last week, the clinical-stage oncology…
Article, News
Prescient Therapeutics exceeds SPP target, delivers top-up placement to accommodate demand
“It is a significant achievement to exceed our target amidst challenging market conditions,” said managing director and CEO Steven Yatomi-Clarke.
Article, News
Prescient Therapeutics at forefront of overcoming challenges, with game-changing CAR-T cell cancer therapies
CAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies it is not without problems, which Prescient Therapeutics…
Article, News
The cancer-fighting tech disabling ‘force fields’ around tumours
SX-listed biotech Prescient Therapeutics has unveiled the second component of its CellPryme cell therapy enhancement platform on stage at the prestigious CAR-TCR Summit in Boston….
Article, News
Prescient Therapeutics debuts CellPryme-A at world’s largest CAR-TCR meeting in Boston
At the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, which is a novel adjuvant designed to be administered to cancer patients in combination…
Categories
- Article (104)
- Media (9)
- News (299)
- Uncategorized (1)
- Webcast Video (7)